Literature DB >> 26948299

Current Topics on Salvage Thoracic Surgery in Patients with Primary Lung Cancer.

Hidetaka Uramoto1.   

Abstract

Salvage primary tumor resection is sometimes considered for isolated local failures after definitive chemoradiation, urgent matters, such as hemoptysis (palliative intent), and in cases judged to be contraindicated for chemotherapy or definite radiation due to severe comorbidities, despite an initial clinical diagnosis of stage III or IV disease. However, salvage surgery is generally considered to be technically more difficult, with a potentially higher morbidity. This review discusses the current topics on salvage thoracic surgery such as the definition of salvage surgery and its outcome, and future perspectives.

Entities:  

Mesh:

Year:  2016        PMID: 26948299      PMCID: PMC4936213          DOI: 10.5761/atcs.ra.16-00019

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  19 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Surgical salvage following stereotactic body radiotherapy for early-stage NSCLC.

Authors:  Z Allibhai; B C J Cho; M Taremi; S Atallah; A Hope; D Hwang; S Keshavjee; M Tsao; K Yasufuku; S-W Kim; A Bezjak
Journal:  Eur Respir J       Date:  2012-04       Impact factor: 16.671

3.  [STRATEGY FOR THE TREATMENT OF UNRESECTABLE LUNG CANCER].

Authors:  Kenji Suzuki
Journal:  Nihon Geka Gakkai Zasshi       Date:  2015-11

4.  Non-small-cell lung cancer: reirradiation for loco-regional relapse previously treated with radiation therapy.

Authors:  Takuhito Tada; Haruyuki Fukuda; Kaoru Matsui; Tomonori Hirashima; Masako Hosono; Yoshie Takada; Yuichi Inoue
Journal:  Int J Clin Oncol       Date:  2005-08       Impact factor: 3.402

5.  Surgical treatment of local recurrence after stereotactic body radiotherapy for primary and metastatic lung cancers.

Authors:  Shinya Neri; Yutaka Takahashi; Takuya Terashi; Hiroshi Hamakawa; Keisuke Tomii; Nobuyuki Katakami; Masaki Kokubo
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

6.  Long-Term Outcomes of Lobectomy for Non-Small Cell Lung Cancer After Definitive Radiation Treatment.

Authors:  Chi-Fu Jeffrey Yang; R Ryan Meyerhoff; Sarah J Stephens; Terry Singhapricha; Christopher B Toomey; Kevin L Anderson; Chris Kelsey; David Harpole; Thomas A D'Amico; Mark F Berry
Journal:  Ann Thorac Surg       Date:  2015-04-15       Impact factor: 4.330

7.  The 30-day mortality and hospital mortality after chest surgery described in the annual reports published by the Japanese Association for Thoracic and Cardiovascular Surgery.

Authors:  Hidetaka Uramoto; Meinoshin Okumura; Shunsuke Endo; Fumihiro Tanaka; Hiroyasu Yokomise; Munetaka Masuda
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-02-06

8.  "Salvage" surgery for primary mediastinal malignancies: is it worthwhile?

Authors:  Francesco Petrella; Francesco Leo; Giulia Veronesi; Piergiorgio Solli; Alessandro Borri; Domenico Galetta; Roberto Gasparri; Rosalba Lembo; Davide Radice; Paolo Scanagatta; Lorenzo Spaggiari
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

9.  Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Nithya Ramnath; Thomas J Dilling; Loren J Harris; Anthony W Kim; Gaetane C Michaud; Alex A Balekian; Rebecca Diekemper; Frank C Detterbeck; Douglas A Arenberg
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

10.  The long-term outcomes of induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.

Authors:  Hidetaka Uramoto; Hirohiko Akiyama; Yuki Nakajima; Hiroyasu Kinoshita; Takuya Inoue; Futoshi Kurimoto; Yu Nishimura; Yoshihiro Saito; Hiroshi Sakai; Kunihiko Kobayashi
Journal:  Case Rep Oncol       Date:  2014-10-23
View more
  8 in total

Review 1.  Salvage surgery after high-dose radiotherapy.

Authors:  Annemie Van Breussegem; Jeroen M Hendriks; Patrick Lauwers; Paul E Van Schil
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

2.  Surgery compared to stereotactic body radiation therapy for early-stage non-small cell lung cancer: better, equivalent or worse?

Authors:  Paul E Van Schil
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

3.  Treatment of a Double Cancer Patient With Primary Inferior Vena Cava Sarcoma and Lung Adenocarcinoma: A Case Report and Literature Review.

Authors:  Xiaohu Guo; Zhengang Wei; Mancai Wang; Youcheng Zhang
Journal:  Front Surg       Date:  2022-04-06

4.  Salvage thoracic surgery in patients with lung cancer: potential indications and benefits.

Authors:  Erkan Kaba; Mehmet Oguzhan Ozyurtkan; Kemal Ayalp; Tugba Cosgun; Mazen Rasmi Alomari; Alper Toker
Journal:  J Cardiothorac Surg       Date:  2018-01-22       Impact factor: 1.637

Review 5.  Surgical Management of Stage IIIA Non-Small Cell Lung Cancer.

Authors:  Paul E Van Schil; Lawek Berzenji; Suresh K Yogeswaran; Jeroen M Hendriks; Patrick Lauwers
Journal:  Front Oncol       Date:  2017-10-26       Impact factor: 6.244

Review 6.  A recurrence-free survivor with chemotherapy-refractory small cell lung cancer after pneumonectomy: A case report and review of the literature.

Authors:  Yong Pan; Feng-Wei Kong; Heng Wang; Xiang Wang; Hui Zhang; Wen-Bin Wu; Miao Zhang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

7.  The Combination Of Weak Expression Of PRDX4 And Very High MIB-1 Labelling Index Independently Predicts Shorter Disease-free Survival In Stage I Lung Adenocarcinoma.

Authors:  Akihiro Shioya; Xin Guo; Nozomu Motono; Seiya Mizuguchi; Nozomu Kurose; Satoko Nakada; Akane Aikawa; Yoshitaka Ikeda; Hidetaka Uramoto; Sohsuke Yamada
Journal:  Int J Med Sci       Date:  2018-06-14       Impact factor: 3.738

8.  The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.

Authors:  Kenichi Mizutani; Xin Guo; Akihiro Shioya; Jing Zhang; Jianbo Zheng; Nozomu Kurose; Hiroaki Ishibashi; Nozomu Motono; Hidetaka Uramoto; Sohsuke Yamada
Journal:  Int J Med Sci       Date:  2019-08-14       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.